Skip to main content
Triangle logo TriangleGet started

Binimetinib (NCT04511013)

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases: a one-minute explainerNCT045110131 min

Binimetinib trial for Acral Lentiginous Melanoma (NCT04511013). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with BRAF-V600-mutant melanoma and measurable brain metastases, without prior systemic treatment for metastatic disease. Eye-origin melanoma is excluded; prior treatment before or after surgery is allowed.

The idea: compare oral encorafenib and binimetinib plus intravenous nivolumab against intravenous ipilimumab and nivolumab. Random assignment selects treatment. The tablets block growth signals; the antibodies release immune brakes. Researchers measure progression, brain-tumor responses, survival and side effects.

This phase 2 study plans 112 patients. SWOG’s Zeynep Eroglu leads it; 303 US sites are recruiting, including Birmingham.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.